Literature DB >> 16917230

Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

May Fakhoury1, Julien Lecordier, Yves Medard, Michel Peuchmaur, Evelyne Jacqz-Agrain.   

Abstract

BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally. Cytokines modulate the expression and functionality of CYP3A and P-gp. Although P-gp results are in disagreement between animal and Caco-2 cell studies, all authors report a decrease in CYP3A levels after exposure to proinflammatory agents. In humans, CYP3A and P-gp mRNA, protein, and functionality levels were higher in various tissues in patients with CD as compared with control groups. Our study's aim was to analyze the impact of systemic inflammation on the expression of CYP3A and P-gp in duodenal normal tissue.
MATERIALS AND METHODS: We compared CYP3A and P-gp mRNA expression in 19 noninflamed duodenal biopsies from children with CD with 19 normal biopsies. We used a real-time reverse-transcription-polymerase chain reaction technique.
RESULTS: There was a high variability in the expression of the 3 CYP3A isoforms and P-gp. CYP3A4, CYP3A5, and P-gp levels were significantly higher in the CD group than in the control group. DISCUSSION AND
CONCLUSIONS: CYP3A and P-gp are involved in the metabolism and transport of many drugs prescribed in CD including corticosteroids. Changes occurring in their duodenal and hepatic expression may explain important interindividual differences in the bioavailability and response to treatment. Further explorations considering protein and activity must be undertaken to understand how such changes affect drug absorption and bioavailability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917230     DOI: 10.1097/00054725-200608000-00011

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  Altered Transport and Metabolism of Phenolic Compounds in Obesity and Diabetes: Implications for Functional Food Development and Assessment.

Authors:  Benjamin W Redan; Kimberly K Buhman; Janet A Novotny; Mario G Ferruzzi
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 2.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

3.  Drug transport into the central nervous system: using newer findings about the blood-brain barriers.

Authors:  William A Banks
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

4.  Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.

Authors:  Souzan B Yanni; P Brian Smith; Daniel K Benjamin; Patrick F Augustijns; Dhiren R Thakker; Pieter P Annaert
Journal:  Biopharm Drug Dispos       Date:  2011-03-30       Impact factor: 1.627

Review 5.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

Review 6.  Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Authors:  K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2015-09       Impact factor: 6.875

7.  Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters.

Authors:  Miriam G Mooij; Ute I Schwarz; Barbara A E de Koning; J Steven Leeder; Roger Gaedigk; Janneke N Samsom; Edwin Spaans; Johannes B van Goudoever; Dick Tibboel; Richard B Kim; Saskia N de Wildt
Journal:  Drug Metab Dispos       Date:  2014-05-14       Impact factor: 3.922

Review 8.  Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Gilbert J Burckart; Lei Zhang; Saskia N de Wildt; Shiew-Mei Huang
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

Review 9.  Pharmacology of morphine in obese patients: clinical implications.

Authors:  Célia Lloret Linares; Xavier Declèves; Jean Michel Oppert; Arnaud Basdevant; Karine Clement; Christophe Bardin; Jean Michel Scherrmann; Jean Pierre Lepine; Jean François Bergmann; Stéphane Mouly
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  The Role of Cytochromes P450 in Infection.

Authors:  Elisavet Stavropoulou; Gratiela G Pircalabioru; Eugenia Bezirtzoglou
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.